Melanoma Proteins in Serum and Urine

描述（由申请人提供）：本提案的总体目标是在黑色素瘤患者的血清和尿液样本中识别诊断癌症的特定标记蛋白或蛋白质表达模式。与许多恶性肿瘤一样，早期发现是成功治疗黑色素瘤的关键。质谱法的最新创新使其成为一项强大的技术，有可能彻底改变癌症诊断标记物的识别。我们的目标是利用这项技术来识别黑色素瘤患者样本中的诊断性蛋白质组学模式。为此目的，提出了下列具体目标：

DESCRIPTION (provided by applicant): The overall objective of this proposal is to identify, in serum and urine samples from melanoma patients, specific marker proteins or patterns of protein expression, which are diagnostic of cancer. As with many malignancies, early detection is critical for successful treatment of melanoma. Recent innovations in mass spectrometry make it a powerful technology that has the potential to revolutionize the identification of diagnostic markers for cancer. We aim to use this technology to identify diagnostic proteomic patterns in samples from melanoma patients. To that end, the following specific aims are proposed: 1. Perform mass spectrometry experiments on serum samples from three melanoma patients and three normal controls. 2. Perform mass spectrometry experiments on urine samples from three melanoma patients and three normal controls. 3. For additional biomarker discovery, samples will be fractionated with additional procedures (glycosylation capture and affinity matrices such as Protein A and dye chromatography) prior to mass spectrometry. 4. Confirm biomarker expression with a larger panel of 15 melanoma samples by an alternative method (e.g. Western blots or ELISA for markers with available antibodies or enzymatic activity for characterized enzymes). Relative expression levels of newly identified proteins will also be compared with known melanoma markers such as lactate dehydrogenase. Preliminary proteomic experiments described herein demonstrate that proteins characteristic of different physiological conditions can be identified using isotope-coded affinity tags (ICAT) coupled with tandem mass spectrometry. The specific aims of this proposal will apply this technology to identification of early markers of malignant melanoma.